3 September 2024
CRISM Therapeutics
Corporation
("CRISM",
"CRISM Therapeutics" or the "Company")
Drug Delivery Method
Validated in Peer Reviewed Journal
CRISM Therapeutics Corporation (AIM:
CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs, is
pleased to confirm that a recent peer reviewed research article,
Local Delivery of
Irinotecan to Recurrent GBM Patients at Reoperation Offers a Safe
Route of Administration, demonstrated that the local
delivery of the chemotherapy drug irinotecan directly into the
border of the resection margin after a tumour has been removed
offers a safe route of administration for glioblastoma patients
with none of the normal side effects associated with traditional
chemotherapy delivered by injection or orally.
The research article, in the journal
Cancers, can be viewed
at:
https://www.mdpi.com/2072-6694/16/17/3008
The research article is co-authored
by academics at the University of Birmingham and the Royal Bristol
Hospital for Children, led by Christopher McConville, Associate
Professor or Pharmaceutics at the University of Birmingham and also
Chief Scientific Officer at CRISM Therapeutics. Cancers is a peer reviewed, open
access, medical journal published by MDPI covering all fields of
oncology.
The safety of the local
administration of irinotecan to the resection margin confirmed by
this research article validates CRISM's decision to use irinotecan
in ChemoSeed as a treatment for high grade gliomas and is expected
to support its clinical trial application. Furthermore, the
article concludes that sustaining the delivery of irinotecan at the
resection margin using an implantable device, such as ChemoSeed,
could improve survival rates in glioblastoma patients.
Commenting on the article in the peer reviewed journal, CRISM
CEO Andrew Webb said: "The
publication of this paper validates CRISM's drug delivery approach
to administer irinotecan locally into the resection margin and we
are pleased that this method of drug delivery is receiving greater
recognition within the oncology community. In addition, this
validation will support our clinical trial application which
remains on track for H2 this year."
-Ends-
Enquiries:
|
Company
|
Nomad and
Broker
|
Financial
PR
|
|
CRISM Therapeutics
Corporation
|
S.P. Angel Corporate Finance
LLP
|
Burson
Buchanan
|
|
Andrew
Webb, CEO
Chris
McConville, CSO
|
Richard
Morrison
Adam
Cowl
|
Mark
Court / Jamie Hooper
CRISM@buchanancomms.co.uk
|
|
via
Burson Buchanan
|
+44 (0)
20 3470 0470
|
+44 (0)
20 7466 5000
|
About CRISM Therapeutics Corporation
CRISM Therapeutics Corporation has
developed an innovative drug delivery technology to improve the
clinical performance of cancer treatments for solid tumours through
the local delivery of chemotherapy drugs.
ChemoSeed, CRISM's lead product, can
be implanted directly into the tumour or the resection margin
following the removal of a tumour. This directs that therapeutic
concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of
treating high-grade glioma, ChemoSeeds can be implanted during
surgery thereby bypassing the blood brain barrier, which prevents
other treatments from being able to reach the tumour and be
effective.
CRISM plans to submit a clinical
trial application in H2 2024 for ChemoSeed® in high-grade
glioma. Based on
preclinical data, the Tessa Jowell BRAIN MATRIX Scientific Advisory
Board has approved ChemoSeed in a phase II platform clinical trial
which is an efficient and cost-effective clinical development
opportunity.
For more information please
visit: https://www.crismtherapeutics.com/